Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study

Plain-language summary

This exploratory study examines whether physical exercise (resistance, endurance and concurrent training) can reduce uremic toxins in people with chronic kidney disease, using biomolecular analyses. Patients with persistent albuminuria and metabolic syndrome who have not taken part in an exercise program for the past six months may join. Conducted by the Catholic University of Brasília, this study without an assigned phase is enrolling participants by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Enrolling by invitation

Sponsor

Catholic University of Brasília

Intervention

Resistance training, Endurance training, Concurrent training

Start date

4/1/2025

Estimated completion

12/31/2035

Countries

Brazil

Related genes

Locations

• Taguatinga, Brazil

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* those diagnosed with chronic kidney disease and presenting persistent albuminuria (\>300mg/g) following KDIGO guidelines;
* metabolic syndrome {i.e., type 2 diabetes mellitus, arterial hypertension (blood pressure \>180/100mmHg), overweight or obesity, and dyslipidemia};
* no complications arising from pre-existing clinical metabolic diseases (i.e., diabetic coma, ketoacidosis, hyperosmolarity, and/or uncontrolled diabetes), as evaluated by a nephrologist;
* absence of neurodegenerative, musculoskeletal, lupus erythematosus, or congenital kidney disease;
* no apparent cardiovascular complications, such as heart failure, severe arrhythmia, angina, or cerebrovascular disease;
* no comorbidities that limit performance in physical tests or training;
* not engaged in exercise programs for at least six months prior to the start of the experimental protocol;
* no smoking or alcohol consumption behavior;
* D-dimer values within normal range (220-500 ng/mL FEU)

Exclusion Criteria:

* regularly engage in physical exercise,
* have suffered a stroke in the last 6 months and/or present autoimmune diseases,
* have unstable cardiac dysfunctions, such as: uncontrolled coronary artery disease, aneurysm at risk of rupture, uncontrolled arrhythmia, uncontrolled hypertension (SBP \> 190 mmHg and/or DBP \> 100 mmHg), heart attack in the last 3 months;
* infectious conditions, Hb \< 8 in the last routine monthly hemodialysis exam;
* musculoskeletal pain;
* fever;
* resting SpO2 lower than 94%;
* restriction by the clinical team.